Recurring was Danaher’s largest product and service line in fiscal 2025, bringing in $20.13B of $24.57B (82%).
| Product and Service | FY 2008 | FY 2009 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recurring | $20.88B | $18.68B | $19.37B | $20.13B | ||||||||||||
| Research & Medical Products | — | — | — | — | ||||||||||||
| Medical & Dental Products | — | — | — | — | ||||||||||||
| Nonrecurring | $5.77B | $5.21B | $4.51B | $4.44B | ||||||||||||
| Analytical & Physical Instrumentation | — | — | — | — | ||||||||||||
| Dental Products | — | — | — | — | ||||||||||||
| Product Identification | — | — | — | — | ||||||||||||
| Motion & Industrial Automation Controls | — | — | — | — | ||||||||||||
| Mechanics & Related Hand Tools | — | — | — | — | ||||||||||||
| All Other | — | — | — | — | ||||||||||||
| Defense | — | — | — | — | ||||||||||||
| Aerospace & Defense | — | — | — | — | ||||||||||||
| Total | $26.64B | $23.89B | $23.88B | $24.57B |
Danaher brought in $24.57B from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 2.9% from $23.88B in fiscal 2024. Recurring was the largest at $20.13B (81.9%), ahead of Nonrecurring at $4.44B (18.1%).
Compared with fiscal 2024, Recurring grew 3.9% to $20.13B, while Nonrecurring fell 1.5% to $4.44B. From fiscal 2022 to 2025, combined revenue from these lines fell from $26.64B to $24.57B, a compound annual decline of 2.7%. Recurring's share of the total rose from 78.4% to 81.9%.
North America was Danaher’s largest region in fiscal 2025, bringing in $10.36B of $24.57B (42%).
| Geography | FY 2009 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | $11.73B | $9.96B | $10.30B | $10.36B | |||||||||||
| High-Growth Markets | $7.71B | $7.19B | $6.87B | $7.02B | |||||||||||
| All Other (Each Country Individually Less Than 5% Of Total) | — | — | — | — | |||||||||||
| U.S. Pension Benefits | — | — | — | — | |||||||||||
| United States | — | — | — | — | |||||||||||
| Western Europe | $5.86B | $5.47B | $5.46B | $5.94B | |||||||||||
| Other | — | — | — | — | |||||||||||
| China | — | — | — | — | |||||||||||
| Other Developed Markets | $1.35B | $1.27B | $1.25B | $1.25B | |||||||||||
| Germany | — | — | — | — | |||||||||||
| Japan | — | — | — | — | |||||||||||
| Total | $26.64B | $23.89B | $23.88B | $24.57B |
Danaher brought in $24.57B from its four regions in fiscal 2025, the year ended December 31, 2025. That was up 2.9% from $23.88B in fiscal 2024. North America was the largest at $10.36B (42.2%), ahead of High-Growth Markets at $7.02B (28.6%) and Western Europe at $5.94B (24.2%). The remaining region, Other Developed Markets, brought in $1.25B.
Compared with fiscal 2024, Western Europe grew fastest, up 8.8% to $5.94B, while Other Developed Markets fell the most, down 0.1% to $1.25B. From fiscal 2022 to 2025, combined revenue from these regions fell from $26.64B to $24.57B, a compound annual decline of 2.7%. North America's share of the total fell from 44.0% to 42.2%.
Diagnostics was Danaher’s largest segment in fiscal 2025, bringing in $9.94B of $24.57B (40%).
| Segment | FY 2009 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostics | $10.85B | $9.58B | $9.79B | $9.94B | |||||||||||
| Life Sciences | $7.04B | $7.14B | $7.33B | $7.33B | |||||||||||
| Biotechnology | $8.76B | $7.17B | $6.76B | $7.29B | |||||||||||
| Life Sciences & Diagnostics | — | — | — | — | |||||||||||
| Environmental & Applied Solutions | — | — | — | — | |||||||||||
| Industrial Technologies | — | — | — | — | |||||||||||
| Environmental | — | — | — | — | |||||||||||
| Test & Measurement | — | — | — | — | |||||||||||
| Dental | — | — | — | — | |||||||||||
| Businesses Contributed To Apex Joint Venture | — | — | — | — | |||||||||||
| Total | $26.64B | $23.89B | $23.88B | $24.57B |
Danaher brought in $24.57B from its three segments in fiscal 2025, the year ended December 31, 2025. That was up 2.9% from $23.88B in fiscal 2024. Diagnostics was the largest at $9.94B (40.5%), ahead of Life Sciences at $7.33B (29.9%) and Biotechnology at $7.29B (29.7%).
Compared with fiscal 2024, Biotechnology grew fastest, up 7.9% to $7.29B. Every segment above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these segments fell from $26.64B to $24.57B, a compound annual decline of 2.7%. Diagnostics' share held steady at about 40.5%.
Danaher (DHR) reports its revenue by product and service, by geography and by segment. In fiscal 2025, Recurring was its largest product and service line, bringing in $20.13B (81.9% of the total), followed by Nonrecurring at $4.44B (18.1%).
Recurring was Danaher's largest product and service line in fiscal 2025, bringing in $20.13B, or 81.9% of the $24.57B total across its two product and service lines.
North America was Danaher's largest region in fiscal 2025, bringing in $10.36B, or 42.2% of the $24.57B total across its four regions.
Diagnostics was Danaher's largest segment in fiscal 2025, bringing in $9.94B, or 40.5% of the $24.57B total across its three segments.
Recurring grew faster than Nonrecurring in fiscal 2025, up 3.9% from $19.37B to $20.13B. Nonrecurring fell 1.5% to $4.44B.
Every figure comes from Danaher's annual financial filings, as reported. Each line keeps the name Danaher gives it, and years follow its fiscal calendar.
Danaher's revenue by product and service goes back to fiscal 2008, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.